DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
7.04
-0.18 (-2.49%)
At close: Jun 30, 2026, 4:00 PM EDT
7.14
+0.10 (1.42%)
After-hours: Jun 30, 2026, 4:37 PM EDT
DiaMedica Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
35
Market Cap
379.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 227.18M |
| Vanda Pharmaceuticals | 217.78M |
| Fennec Pharmaceuticals | 51.00M |
| OmniAb | 28.94M |
| X4 Pharmaceuticals | 9.01M |
| Upstream Bio | 3.32M |
| Compass Therapeutics | 850.00K |
DMAC News
- 7 days ago - DiaMedica Therapeutics announces dosing of first two patients in DM199 study - TheFly
- 7 days ago - DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction - Business Wire
- 14 days ago - DiaMedica Therapeutics receives written response from FDA on DM199 - TheFly
- 14 days ago - DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program - Business Wire
- 4 weeks ago - DiaMedica Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026 - Business Wire
- 5 weeks ago - DiaMedica announces 75% enrollment milestone in ReMEDy2 Phase 2/3 trial - TheFly
- 5 weeks ago - DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial - Business Wire